Nuvation Bio, Inc. (NUVB)
6.835
+0.06
(+0.96%)
USD |
NYSE |
Sep 04, 13:52
Nuvation Bio Cash from Investing (Quarterly) : 5.991M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.991M |
| March 31, 2026 | -43.64M |
| December 31, 2025 | 87.08M |
| September 30, 2025 | -96.62M |
| June 30, 2025 | 54.88M |
| March 31, 2025 | 54.18M |
| December 31, 2024 | 51.77M |
| September 30, 2024 | 29.12M |
| June 30, 2024 | 34.27M |
| March 31, 2024 | 7.542M |
| December 31, 2023 | 33.16M |
| September 30, 2023 | -9.592M |
| June 30, 2023 | 37.35M |
| Date | Value |
|---|---|
| March 31, 2023 | -52.00M |
| December 31, 2022 | -21.83M |
| September 30, 2022 | 64.20M |
| June 30, 2022 | 26.63M |
| March 31, 2022 | -5.551M |
| December 31, 2021 | -189.26M |
| September 30, 2021 | -91.72M |
| June 30, 2021 | -172.60M |
| March 31, 2021 | -1.085M |
| December 31, 2020 | -98.26M |
| September 30, 2020 | 6.517M |
| June 30, 2020 | 10.82M |
| March 31, 2020 | 10.61M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Bristol Myers Squibb Co. | -1.614B |
| Johnson & Johnson | -1.11B |
| Pfizer Inc. | 2.106B |
| Eli Lilly & Co. | -15.40B |
| Merck & Co., Inc. | -5.602B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -42.97M |
| Cash from Financing (Quarterly) | 170.53M |
| Free Cash Flow | -128.92M |
| Free Cash Flow Per Share (Quarterly) | -0.1239 |
| Free Cash Flow to Equity (Quarterly) | -242.50M |
| Free Cash Flow to Firm (Quarterly) | -36.46M |
| Free Cash Flow Yield | -5.34% |